What type of study is this?

This is a Literature Review study.

August 17, 2025Open Access

Dual Nature of Mitochondrial Integrated Stress Response: Molecular Switches from Protection to Pathology

JJJisu JeongNaver (South Korea)JKJung Hyun KimPohang University of Science and Technology MKMan S. KimKyung Hee University

Key Points

Activation of the mitochondrial integrated stress response reveals a dual role, providing protection or leading to pathology depending on cellular context.
Clinical trials investigating ISR therapies, particularly in ALS, have faced significant setbacks, demonstrating the complexity of therapeutic approaches.
Recent research shifts from simplistic models to understanding complex, context-dependent networks within the stress response pathways.
The need for precision medicine emerges from trial failures, emphasizing the importance of tailoring therapies to specific disease mechanisms and temporal dynamics.

Abstract

Background: The mitochondrial integrated stress response (ISR) represents a fundamental cellular adaptation mechanism with dual protective and pathological roles. We critically analyzed current literature on ISR mechanisms, focusing on recent paradigm shifts including the 2020 discovery of the OMA1-DELE1-HRI axis, emerging controversies over context-dependent activation patterns, and the January 2025 clinical trial failures that have reshaped the therapeutic landscape. Methods: We reviewed recent literature (2020–2025) examining ISR mechanisms, clinical trials, and therapeutic developments through comprehensive database searches. Results: The field has evolved from simple linear pathway models to recognition of complex, context-dependent networks. Recent findings reveal that ISR activation mechanisms vary dramatically based on cellular metabolic state, with distinct pathways operating in proliferating versus differentiated cells. The “dark microglia” phenotype in neurodegeneration and DR5-mediated apoptotic switches exemplify pathological ISR manifestations, while adaptive responses include metabolic reprogramming and quality control enhancement. Conclusions: The 2025 failures of DNL343 and ABBV-CLS-7262 in ALS trials underscore the need for precision medicine approaches that account for context-dependent ISR functions, temporal dynamics, and disease-specific mechanisms.

KI fragen

Bookmark

View Full Paper

Cite This Study

Jeong et al. (Wed,) studied this question.

synapsesocial.com/papers/68a36a360a429f797332e5ea https://doi.org/https://doi.org/10.3390/genes16080957

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

KI fragen

Bookmark

View Full Paper